Integrated Lead Discovery Collaboration
OSI is the pioneer in the development and maturation of high-throughput screening (HTS) with over 16 years of experiences. OSI has a proven track record in leads discovery: Tarceva® was discovered by OSI’s lead discovery group and over 14 drug candidates have entered into clinical development. The collaborations covered a wide range of therapeutic areas, including oncology, cardiovascular disease, diabetes, obesity, dermatology, asthma, and other respiratory diseases.

OSI’s drug discovery expertise is available to partners seeking to expedite or initiate small molecule drug discovery programs. OSI offers a full spectrum of services to help you streamline your drug discovery programs:

• Protein Production and Assay Development for a diverse range of drug targets.
• HTS of 100,000 compounds against a specific target(s).
• Selectivity profiling of hits against a panel of kinases
• Lead Identification via Affinity Selection by Mass Spectrometry (ASMS) for non enzyme targets.
• Virtual screening of external compound collections where target structure is available.
• Virtual screening of internal compound library
• Screening for solubility, permeability (PAMPA), microsomal stability and CYP inhibition.
• Metabolic profiling of hits in vivo.
• Exploration of initial Structure Activity Relationships around hits from HTS.
• Drug Discovery Consulting expertise to enable efficient and cost effective identification of IND track candidates.

For more information on Integrated Lead Discovery collaborations, please contact Dr. Neil Gibson (Chief Scientific Officer) at 631-962-0699 or ngibson@osip.com